6 research outputs found

    Solitary plasmacytoma of the calvarium

    No full text
    A solitary plasmacytoma of the calvarium was removed radically without postoperative radiotherapy. A 69-year-old female patient was operated for a giant solitary plasmacytoma in the frontal region and the follow-up over 10 years revealed no recurrence. The authors discuss that solitary plasmacytoma of the calvarium may have a good prognosis if radically removed and the radiotherapy may not be necessary

    Preventive effect of hesperidin against inflammation in CD-1 mouse skin caused by tumor promoter

    No full text
    Ow earlier studies have shown thar the flavonoid hesperidin inhibits tumor promotion in a two stage skin tumorigenesis protocol in CD-l mice. In this study hesperidin's significant protection (p<0.0001) against 12-0-tetradecanoylphorbol-13-acetate (TPA) induced edema in CD-I mouse ear will be presented. Hesperidin also afforded significant protection against TPA induced hyperplasia in the dorsal skin through multiple application prior to TPA. Protection by hesperidin was 93% of the epidermal thickness and 100% of the vertical cell layers The data also indicate the protective effect of hesperidin against TPA caused infiltration of neutrophils by 73%. These results suggest that hesperidin may possess potential as chemopreventive agent against tumor promoter induced inflammation and hyperplasia

    Effects of tibolone and hormone therapy (estradiol and medroxyprogesterone acetate) on the late toxic effects of radiotherapy in cervical cancer survivors: a prospective, double-blind, randomized, placebo-controlled trial

    No full text
    Purpose: The primary objective of this study was to investigate the efficacy of tibolone and estrogen therapies to prevent the late toxic effects of radiotherapy in the vagina in cervical cancer survivors who received radiotherapy. A secondary objective included how these therapies affected sexual life. Material and Methods: In the placebo arm, the patients received a placebo. In the tibolone arm, the patients received tibolone at a dosage of 2.5 mg daily. In the estrogen arm, patients received 0.625 mg estradiol (E2) and five mg medroxyprogesterone acetate (IVEPA) daily. The patients were assessed with the LENT-SOMA (Late Effects Normal Tissues-Subjective Objective Management and Analytic) scoring system, vaginal impression, female sexual function index (FSFI), and routine gynecological examination. Results: The LENT SOMA total score was significantly higher in the baseline measurement in all arms of the study (p<0.001). The vaginal length significantly increased in the tibolone arm (7.17 +/- 0.98 vs. 7.69 +/- 0.91;p<0.001) and E2/MPA arm (7.29 +/- 1.37 vs. 7.80 +/- 1.29; p = 0.005). The changes in FSFI total score significantly improved in the tibolone arm (16.06 +/- 6.92 vs. 22.19 +/- 6.14 vs. 26.02 +/- 12.35;p = 0.042). Conclusions: The evidence suggested that short-term tibolone or E2/MPA use appeared to reduce the late toxic effects of radiotherapy and increase the vaginal measurements, while tibolone improved sexual function especially, in cervical cancer survivors
    corecore